Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Clinical Pathology

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1309/3JLTFNNEDQHB4A0PPMID 15080298
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications

  2004cited by this paper
• Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues

  2003cited by this paper
• Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.

  2003cited by this paper
• Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.

  2003cited by this paper
• Sudden onset of the blastic phase of chronic myelogenous leukemia

  2003cited by this paper
• BCR/ABL Induces Expression of Vascular Endothelial Growth Factor and its Transcriptional Activator, Hypoxia Inducible Factor-1α, through a Pathway Involving PI3-Kinase and the Mammalian Target of Rapamycin (mTOR)

  2002cited by this paper
• World Health Organization Classification of Tumours

  2002cited by this paper
• Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

  2002cited by this paper
• Increased angiogenesis in the bone marrow of patients with systemic mastocytosis.

  2002cited by this paper
• Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.

  2002cited by this paper
• Chronic myelogenous leukemia: mechanisms underlying disease progression

  2002cited by this paper
• Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants

  2002cited by this paper
• Gene Expression Profiling in Chronic Myeloid Leukemia Patients Treated with Hydroxyurea

  2002cited by this paper
• Soluble angiogenic factors: Implications for chronic myeloproliferative disorders

  2002cited by this paper
• Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia

  2002cited by this paper
• BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

  2002cited by this paper
• Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia.

  2002cited by this paper
• Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.

  2002cited by this paper
• Mechanisms of Transformation by the BCR/ABL Oncogene

  2001cited by this paper
• Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells

  2001cited by this paper
• Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

  2001influential reference
• bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use

  2001cited by this paper
• Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.

  2000cited by this paper
• CHRONIC MYELOGENOUS LEUKAEMIA

  2000cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

  2000cited by this paper
• Chronic myeloid leukemia.

  1999cited by this paper
• Chronic Myelogenous Leukemia: Biology and Therapy

  1999cited by this paper
• Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

  1999cited by this paper
• p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts*

  1998cited by this paper
• The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings.

  1998influential reference
• Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia

  1997cited by this paper
• One-hour downward alkaline capillary transfer for blotting of DNA and RNA.

  1992cited by this paper
• The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.

  1986cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper
• Chronic myelogenous leukaemia

  1973cited by this paper
• Chromosome studies in human leukemia. II. Chronic granulocytic leukemia.

  1961cited by this paper

• IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia

  2023cites this paper
• Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review.

  2021cites this paper
• Serum Vascular Endothelial Gowth Factor Correlates with Hasford Score in Chronic Myeloid Leukemia

  2021influential citation
• The underestimated role of basophils in Ph+ chronic myeloid leukaemia

  2018cites this paper
• Effects of vascular endothelial growth factors and their receptors on megakaryocytes and platelets and related diseases

  2018cites this paper
• Targeted drug delivery for tumor therapy inside the bone marrow.

  2018cites this paper
• Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.

  2018cites this paper
• Retinoic Acid Receptor γ Activity in Mesenchymal Stem Cells Regulates Endochondral Bone, Angiogenesis, and B Lymphopoiesis

  2018cites this paper
• The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications.

  2017cites this paper
• ELEVATED PLASMA LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND HEPATOCYTE GROW TH FACTOR: CLINICAL SIGNIFICANCE AND CORRELATION W ITH TUM OR BURDEN IN PATIENTS WITH CHRONIC M YELOID LEUKEMIA

  2017cites this paper
• Role of Microvessel Density and Vascular Endothelial Growth Factor in Angiogenesis of Hematological Malignancies

  2016cites this paper
• Significance of neuropilin-1 mRNA expression in chronic myeloid leukemia

  2016cites this paper
• Hypoxia Enhances Wilm's Tumor 1 and Vascular Endothelial Growth Factor Isoform Expression in Leukemia Cells

  2016influential citation
• Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms

  2015cites this paper
• Circulating endothelial cells are increased in chronic myeloid leukemia blast crisis

  2015cites this paper
• HERG1 K+ channels on the leukemic cells mediated angiogenesis in vitro

  2014cites this paper
• Targeting the vascular endothelial growth factor in hematologic malignancies

  2012influential citation
• Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.

  2012cites this paper
• Proliferation and differentiation potential of CD133+ and CD34+ populations from the bone marrow and mobilized peripheral blood

  2011cites this paper
• Epigenetic regulation of cathepsin L expression in chronic myeloid leukaemia

  2011cites this paper
• Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.

  2010cites this paper
• Bone marrow angiogenesis in aplastic anemia – a study of CD 34 and VEGF expression in bone marrow biopsies

  2009cites this paper
• ORIGINAL ARTICLE Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia

  2008cites this paper
• Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia

  2008cites this paper
• Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2

  2007cites this paper
• Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy

  2007cites this paper
• VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues

  2007cites this paper
• Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases

  2007cites this paper
• Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

  2007cites this paper
• Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia.

  2006cites this paper
• Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category

  2006cites this paper
• Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia

  2006cites this paper
• The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

  2005cites this paper